The ongoing phase II HERTHENA-Lung01 study is currently evaluating HER3-DXd in patients with metastatic NSCLC following at least one EGFR TKI and one platinum-based chemotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.